LENVATINIB

Description

Lenvatinib – Targeted Therapy for Thyroid, Liver, and Kidney Cancer

Lenvatinib is a prescription targeted cancer therapy that belongs to the class of multi-kinase inhibitors. It is widely used in the treatment of differentiated thyroid cancer (DTC), hepatocellular carcinoma (HCC), and advanced renal cell carcinoma (RCC). Lenvatinib works by blocking multiple receptors involved in tumor growth and angiogenesis, including VEGFR, FGFR, PDGFR, RET, and KIT, thereby slowing disease progression.

At Oncomed Pharmacy, we provide authentic Lenvatinib capsules from trusted manufacturers, ensuring safe, effective, and high-quality targeted oncology medicines.

Key Features of Lenvatinib

• Indications:

o Differentiated thyroid cancer (radioactive iodine-refractory)

o Hepatocellular carcinoma (HCC), as monotherapy or in combination with pembrolizumab

o Advanced renal cell carcinoma (RCC), in combination with everolimus

• Formulation: Oral capsules available in multiple strengths (e.g., 4 mg, 10 mg).
• Mechanism of Action: Multi-kinase inhibitor that blocks angiogenesis and tumor proliferation by targeting VEGFR, FGFR, PDGFR, RET, and KIT pathways.
• Patient Benefit: Oral targeted therapy that delays disease progression and extends survival in advanced cancers.

Why Buy Lenvatinib from Oncomed Pharmacy?

• 100% genuine and quality-tested targeted therapy.
• Available in multiple strengths for flexible dosing.
• Affordable pricing with secure countrywide delivery.
• Trusted oncology pharmacy specializing in advanced cancer treatments.

Uses of Lenvatinib

• First-line therapy for radioiodine-refractory thyroid cancer.
• Standard therapy for hepatocellular carcinoma, either alone or with immune checkpoint inhibitors.
• Effective in renal cell carcinoma when combined with everolimus.

• Investigational and off-label use in other solid tumors.